Abstracts tagged "rheumatoid arthritis"

Abstract Number: 465 • 2014 ACR/ARHP Annual Meeting
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
S. Cohen¹, Jeffrey R. Curtis², Roy Fleischmann¹ and Y. Chen³, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of Alabama, Birmingham, AL, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Miguel Perez-Aso¹, M. Carmen Montesinos², Aranzazu Mediero³, Peter H. Schafer⁴ and Bruce N. Cronstein⁵, ¹545 1st Ave., New York University, New York City, NY, ²Departament de Farmacologia, Facultat de Farmàcia,, Universitat de València, Valencia, Spain, ³Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ⁴Celgene Corporation, Celgene Corporation, Summit, NJ, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…
Abstract Number: 1031 • 2014 ACR/ARHP Annual Meeting
Induction of Pro-Apoptotic Noxa Expression By Ursolic Acid Sensitizes Rheumatoid Arthritis Synovial Fibroblasts to Apoptosis: A Role of Mir-181a
Salahuddin Ahmed¹, Laura Walsh², Anil Singh¹, Maria Beamer³, Kuladeep Sudini⁴ and Douglas Leaman⁴, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH, ³Department of Pharmacology, Department of Pharmacology, University of Toledo, Toledo, OH, ⁴Department of Biological Sciences, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the paucity of pro-apoptotic protein expression may significantly contribute to the resistance of synovial fibroblasts (FLS) to apoptosis. In the…
Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson² and Jeremy Sokolove², ¹Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…
Abstract Number: 2356 • 2014 ACR/ARHP Annual Meeting
Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes
Yun-Hong Cheon¹, Wan-Hee Yoo², Young Sun Suh³, Min-Gyu Jeon⁴, Hyun-Ok Kim³ and Sang-Il Lee³, ¹Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Chonbuk National University School of Medicine, Jeonju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁴Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, South Korea
Background/Purpose TSAHC, a toluenesulfonylamido-chalcone, 4-(p-toluenesulfonylamido)-4-hydroxychalcone is a compound to block proliferation and metastatic potential of cancer cells. Fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLS) have inflammatory…
Abstract Number: 940 • 2014 ACR/ARHP Annual Meeting
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Judith Haschka^1,2, Jürgen Rech³, Matthias Englbrecht¹, Stephanie Finzel¹, Michaela Reiser¹, Axel J. Hueber¹, Arnd Kleyer¹, Hans-Peter Tony⁴, Martin Fleck⁵, Karin Manger⁶, Wolfgang Ochs⁷, Jörg Wendler⁸, Hanns-Martin Lorenz⁹, Hubert Nüßlein¹⁰, Rieke Alten¹¹, Winfried Demary¹² and Georg Schett¹, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 2, The VINFORCE Study Group, St. Vincent Hospital Vienna, Vienna, Austria, ³Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 2, University Hospital Würzburg, Würzburg, Germany, ⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ⁶Rheumatology Practice Bamberg, Bamberg, Germany, ⁷Rheumatology Practice Bayreuth, Bayreuth, Germany, ⁸Rheumatology Practice Erlangen, Erlangen, Germany, ⁹Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ¹⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ¹¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹²Rheumatolgy Practice Hildesheim, Hildesheim, Germany
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…
Abstract Number: 347 • 2014 ACR/ARHP Annual Meeting
Salt Aggravates Arthritis By Th17 Polarization
Seung Min Jung¹, Hong Ki Min¹, Jung Hee Koh¹, Jin Young Kang¹, Jennifer Lee¹, Seung-Ki Kwok², Kyung-Su Park³, Hyeok-Jae Ko⁴, Wan-Uk Kim⁵, Ho-Youn Kim¹, Sung-Hwan Park¹ and Ji Hyeon Ju¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea, ⁵Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose Sodium chloride (NaCl) recently has been shown to drive autoimmune diseases through the induction of pathogenic interleukin 17-producing T helper (Th17) cells. This study…
Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Iris Hecht¹, Kay McNamee², Aviad Keren³, Joseph R. Podojil⁴, Ilan Vaknin¹, Anat Oren¹, Galit Rotman¹, Eyal Neria¹, Stephen D. Miller⁴, Amos Gilhar³ and Richard O. Williams², ¹Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Technion Institute of Technology, Haifa, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Nancy A. Baker¹, Heather Eng², Juan (June) Feng², Jason Lyons², Yong Gil Hwang³, Kimberly P. Liang⁴ and Larry W. Moreland⁵, ¹Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…
Abstract Number: 324 • 2014 ACR/ARHP Annual Meeting
Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail
Chrong-Reen Wang^1,2, Shih-Yao Chen³, Ai-Li Shiau⁴, I-Ming Jou^5,6, Ming-Fei Liu^1,2 and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁵Orthopedics, National Cheng Kung University Medical College, Tainan, Taiwan, ⁶Orthopedics, National Cheng Kung University Hospital, Tainan, Taiwan
Background/Purpose: Transcription factor Snail plays active roles in various biological functions and is involved in many disease states. We hypothesized that this molecule regulates TNF-α-mediated…
Abstract Number: 2340 • 2014 ACR/ARHP Annual Meeting
Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL-2Rγ^null Mice
Yosuke Nagasawa¹, Natsumi Ikumi², Takamasa Nozaki¹, Hirotake Inomata¹, Kenichi Imadome³, Noboru Kitamura¹, Mitsuhiro Iwata¹, Shigeyoshi Fujiwara⁴ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Department of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan, ⁴Department of Iinfectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose Various studies of the relationship between Epstein-Barr virus (EBV) and rheumatoid arthritis (RA) have not produced convincing evidence. Many human viruses do not infect…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
J. R. Curtis¹, H. Schulze-Koops², L Takiya³, C. A. Mebus⁴, K. Terry⁴, R. Chew⁴ and T. V. Jones³, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Munich, Munich, Germany, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Mattias Svensson¹, Karin Andersson¹, Malin Erlandsson¹, Ing-Marie Jonsson² and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].